JAMES DODDS: Open Payments
NPI 1285244764 · SALEM, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$671 in 46 payments from 14 companies in 2025. Trend: 2023 $334 · 2024 $637 · 2025 $671
Food & beverage: $671
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 19 | $220 |
| Axsome Therapeutics, Inc. | 5 | $107 |
| Novartis Pharmaceuticals Corporation | 4 | $86 |
| Phathom Pharmaceuticals, Inc. | 4 | $42 |
| Amgen Inc. | 2 | $34 |
| Otsuka America Pharmaceutical, Inc. | 2 | $31 |
| Aimmune Therapeutics, Inc. | 2 | $30 |
| Edwards Lifesciences Corporation | 1 | $24 |
| SANOFI-AVENTIS U.S. LLC | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
Products named: LEQVIO, QULIPTA, VRAYLAR, UBRELVY, Auvelity, VOQUEZNA, Sunosi, EVENITY.
Industry payments across UT — which companies pay providers there.
